Last viewed: GLMD

Prices are updated after-hours

GLMD 2020 - 05 - 15

Galmed Pharmaceuticals Ltd.

GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

(0.0% 1d) (18.1% 1m) (-99.5% 1y) (0.0% 2d) (4.4% 3d) (-11.7% 7d) (-52.02% volume)
Earnings Calendar: 2022-11-07
Market Cap: $ 1,851,129
http://www.galmedpharma.com
Sec Filling | Patents | 21 employees

(IL) Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

diabetes diabetic israel hepatitis nash treatment

add to watch list Paper trade email alert is off

Press-releases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Published: 2024-04-04 (Crawled : 21:00) - prnewswire.com
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| 12.12% | O: -2.42% H: 5.59% C: 5.59%
report year pharmaceuticals for

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| 6.02% | O: 17.48% H: 0.0% C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash

Rheumatoid Arthritis Drugs Market to grow by USD 16.04 billion from 2023 to 2028; North America to account for 39% of market growth- Technavio
Published: 2023-12-04 (Crawled : 18:00) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K

|

Health Technology

| -18.56% | O: 0.26% H: 0.0% C: 0.0%
GLAXF | $20.2 -14.18% 510

|

Health Technology

| 9.78% | O: -2.6% H: 1.1% C: -1.18%
SNYNF | News | $92.7 -2.18% 1.4K

|

Health Technology

| -1.28% | O: 0.27% H: 0.12% C: 0.12%
NVSEF | News | $93.6375 6.88% 82K

|

Health Technology

| -4.4% | O: -1.1% H: 0.0% C: 0.0%
ALPMY | News | $9.46 -1.11% 500K

|

| -22.81% | O: 0.0% H: 0.5% C: 0.17%
NVS | News | $92.57 -0.55% 0.0% 910K

|

Health Technology

| -5.97% | O: -1.86% H: 0.34% C: -0.19%
GSK | $39.27 -0.83% 0.01% 2.2M

|

Health Technology

| 8.11% | O: -1.01% H: 0.39% C: 0.19%
ABBV | $164.66 0.25% -0.15% 4.5M

|

Health Technology

| 14.33% | O: 0.51% H: 0.68% C: 0.32%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -1.44% | O: -0.5% H: 0.0% C: 0.0%
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -5.1% | O: 0.03% H: 2.44% C: -1.03%
AMGN | $262.77 -0.49% -0.49% 2M

|

Health Technology

| -2.06% | O: -0.25% H: 0.05% C: -0.37%
america market

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Published: 2023-11-20 (Crawled : 23:00) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -9.11% | O: -0.52% H: 7.23% C: 7.23%
study

Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
AZN | $68.36 -0.25% -0.25% 4M

|

Health Technology

| Email alert Add to watchlist
GALT | $3.36 -0.59% -0.6% 150K

|

Health Technology

| Email alert Add to watchlist
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| Email alert Add to watchlist
GNFT | $3.63 4.03% 3.5K

|

Health Technology

| Email alert Add to watchlist
ICPT | $19.0 -0.05% 4M

|

Health Technology

| Email alert Add to watchlist
IVA | $3.28 1.86% 1.83% 12K

|

Health Technology

| Email alert Add to watchlist
MDGL M | $222.18 -2.7% -2.8% 270K

|

Health Technology

| Email alert Add to watchlist
NVS | News | $92.57 -0.55% 0.0% 910K

|

Health Technology

| Email alert Add to watchlist
NVSEF | News | $93.6375 6.88% 82K

|

Health Technology

| Email alert Add to watchlist
AZNCF | $140.15 -4.19% 560

|

Health Technology

| Email alert Add to watchlist
IVEVF | $3.73 0% 1K

|

| Email alert Add to watchlist
liver disease global nash market

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Published: 2023-09-26 (Crawled : 14:30) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -37.29% | O: -2.0% H: 5.0% C: -0.66%
patent treatment fibrosis aramchol

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Published: 2023-09-22 (Crawled : 20:00) - prnewswire.com
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| Email alert Add to watchlist
nasdaq pharmaceuticals

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Published: 2023-07-14 (Crawled : 15:00) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -82.21% | O: 1.92% H: 0.0% C: -31.6%
offering pharmaceuticals

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
Published: 2023-07-10 (Crawled : 14:00) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -86.04% | O: 9.43% H: 0.0% C: -13.1%
trial

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Published: 2023-06-01 (Crawled : 18:00) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K

|

Health Technology

| -91.97% | O: 0.0% H: 6.94% C: 0.43%
pharmaceuticals financial results

See all

Last 15 days Sec forms

File Id

Form

Published Date

Transaction Date

Direction

Code

Amount Transacted

Owned Amount

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | $1.02 155.0% 57.94% 120M

|

ZCMD | $2.86 108.76% 52.1% 2.3M

|

Commercial Services

INVO | $1.555 104.6% 51.13% 5M

|

Health Technology

ISPC | $0.437 105.16% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | $0.92 84.0% 45.65% 1.6M

|

OST | $0.499 21.38% 45.26% 1.9M

|

XPON | $3.1 60.62% 37.74% 17M

|

TIRX | $0.7 44.39% 30.74% 58M

|

BNTC | $6.92 44.17% 30.64% 3.5M

|

Health Technology

GGE | $0.035 19.86% 29.3% 64M

|

Last 48 Hours Insiders Buying

SNDA P 3000 | $29.61 3.35% 0.0% 30K

|

| 22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K

|

| 21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M

|

Distribution Services

| 20:00
QCRH | $55.405 1.33% 1.31% 54K

|

| 18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K

|

Health Technology

| 18:00
VUZI | $1.26 3.28% 3.17% 1M

|

Electronic Technology

| 18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K

|

| 15:00
RELL | $10.15 2.94% 2.86% 94K

|

Electronic Technology

| 13:30
IZEA | $2.65 4.74% 4.53% 31K

|

Technology Services

| 00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M

|

| 22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K

|

| 22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K

|

Energy Minerals

| 21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M

|

Health Technology

| 16:30
RMCF | $3.61 2.27% 2.22% 18K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar